Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your own blood and fat heal aching joints? new trial aims to find out

NCT ID NCT07434115

Symptom relief Sponsor: PROREGEN Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This early-phase trial will test four orthobiologic treatments—PRP, bone marrow concentrate, hyaluronic acid, and nanofat—in 300 adults with various muscle, joint, tendon, or bone conditions. The goal is to see if these natural substances can reduce pain and improve joint function over six months. Participants will receive injections as part of routine care and report their pain and function using standard questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Platelet-rich plasma (PRP), bone marrow concentrate, hyaluronic acid, and nanofat
What this could lead to
If successful, this could point toward effective, minimally invasive options for easing pain and improving joint function in common musculoskeletal conditions.
What could go wrong
This is a very early, single-center study with no control group, so results may not be reliable or generalizable. The treatments are not yet proven to work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 or older; * Clinical and/or radiological diagnosis of an eligible musculoskeletal condition; * Formal clinical indication for treatment with orthobiological agents, according to routine care; * Regular access to the WhatsApp application, ensuring the necessary communication for sending and receiving digital questionnaires and other study instructions; * Ability to understand the study and sign the Informed Consent Form. Exclusion Criteria: * Medical contraindication to the use of orthobiologics (e.g., active infection, severe hematological diseases, active cancer); * Recent use (≤3 months) of orthobiologic therapies in the same area to be treated; * Pregnant or breastfeeding women; * Cognitive or psychiatric diseases that prevent adequate clinical follow-up; * Simultaneous participation in another interventional clinical study with the same therapeutic purpose.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Musculoskeletal diseases or conditions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

musculoskeletal system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Musculoskeletal diseases or conditions

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clínica Proregen | Clínica Ortopédica em Bento | Dr. André Kruel

    RECRUITING

    Bento Gonçalves, Rio Grande do Sul, 95700-066, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.